Trikafta access in the UAE: the EDE named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Trikafta is the Vertex Pharmaceuticals triple-combination CFTR modulator approved by the US FDA in October 2019 for cystic fibrosis patients aged 2 years and older who carry at least one F508del mutation in the CFTR gene. In the United Arab Emirates the product (also marketed in some markets as Kaftrio) has been available through hospital channels, but local stocking in retail pharmacies is sporadic and continuity gaps are common. UAE families who already have a child or adolescent on Trikafta therapy frequently turn to a named-patient pathway when local supply lapses, when payer pathways prefer older modulators, or when the family chooses to stay on Trikafta rather than accept a substitution. The Emirates Drug Establishment (EDE), which assumed the federal drug-import function from MOHAP on 29 December 2025, is the authority that processes the unregistered-medicine import permit.

Reserved for you.

Why families in the UAE reach for Trikafta through NPP

The UAE operates one of the most developed pharmaceutical regulatory environments in the Gulf Cooperation Council. Even with that maturity, three structural access gaps appear repeatedly. A drug can be on the federal register but absent from a particular hospital pharmacy. A drug can be registered for one indication and prescribed for another FDA-approved use that is not on the local label. A drug can be approved by the FDA and never registered in the UAE at all. For Trikafta, the dominant pattern in this market is the first: registered in the country, available in some tertiary hospitals, but stocking can lapse for weeks at a time, and a chronic CFTR modulator cannot tolerate weeks-long gaps.

The named-patient case for Trikafta also rests on the drug itself. Roughly 90 percent of people with cystic fibrosis carry at least one F508del allele, which is the eligibility gate for Trikafta. The pediatric label was extended to ages 6 and older in June 2021, then to ages 2 and older in April 2023, which broadened the population of UAE children eligible for the drug. Vertex launched the once-daily successor Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) in the United States in December 2024, and some payer systems are beginning to push new starts toward that successor. Many established Trikafta patients in the Gulf, supported by longer real-world experience and existing prior-authorization templates, prefer to stay on Trikafta. A cross-border named-patient route gives them that continuity.

The EDE named-patient pathway for Trikafta

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered locally, or is registered but not currently stocked, is the unregistered-medicine import permit. Until 29 December 2025 the application sat with the Ministry of Health and Prevention (MOHAP). It now flows through the EDE portal at ede.gov.ae under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable or not available.

For Trikafta the clinical-justification angle is genotype-specific. A complete application typically includes:

• A clinical justification letter from the treating CF physician naming the patient's CFTR genotype (at least one F508del mutation, or another responsive variant on the current FDA label), prior modulator history if any, clinical status, and why this specific drug is required
• The treating physician's UAE medical license (MOHAP, DHA, DOH, or Sharjah Health Authority, depending on practice location)
• An anonymised patient identifier where the EDE submission allows
• Product details: Trikafta, elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 75 mg morning tablet and ivacaftor 150 mg evening tablet (or the appropriate pediatric strength or granule packet), manufacturer Vertex Pharmaceuticals, pack size, quantity requested, intended treatment duration
• The destination dispensing facility license number and the pharmacy in charge
• A chain-of-custody plan from the US specialty-pharmacy source through the importer to the hospital pharmacy

Approval timelines for routine cases are typically 5 to 15 business days. For Trikafta, where the molecule is well-characterised and the F508del documentation is unambiguous, cases generally fall in that routine window. Complex cases (first import of the molecule through a smaller importer, non-F508del responsive variant requiring extra label review) can extend to 4 to 6 weeks. Trikafta is room-temperature stable, so timelines are not pinched by cold-chain logistics, but the pediatric granule packets carry their own dispensing-pharmacy verification steps. The CF center or family physician's clinical letter is the cornerstone of the package regardless of who files.

Where Trikafta gets dispensed in the UAE

Trikafta is an oral therapy. There is no infusion-centre requirement, and the dispensing footprint is broader than for cold-chain biologics. Tertiary hospitals with established import-pharmacy infrastructure handle Trikafta as routine workflow. The UAE institutions that file named-patient imports as established practice include Cleveland Clinic Abu Dhabi (M42 group, Al Maryah Island), Sheikh Khalifa Medical City in Abu Dhabi (SEHA network), Tawam Hospital in Al Ain (SEHA pediatric oncology and pulmonology), American Hospital Dubai (Mayo Clinic Care Network), King's College Hospital London Dubai, Mediclinic City Hospital in Dubai Healthcare City, and the larger NMC Healthcare sites across the emirates.

For pediatric CF cases the natural homes are the pediatric pulmonology services at Cleveland Clinic Abu Dhabi, the pediatric service at SKMC, the pediatric oncology and respiratory programs at Tawam, and the pediatric service at American Hospital Dubai. Families resident in the Northern Emirates (Ajman, Umm Al Quwain, Ras Al Khaimah, Fujairah) without a local CF center typically route to one of the Dubai or Abu Dhabi facilities where their physician holds joint privileges or where co-management with a UAE-licensed specialist is in place. Smaller clinics without import infrastructure route the file through a Dubai- or Abu Dhabi-based specialty importer holding a pharmaceutical establishment license; the importer files the EDE permit and delivers under chain-of-custody documentation to the prescribing hospital's outpatient pharmacy.

Real cost picture for Trikafta in the UAE

US wholesale acquisition cost for Trikafta is approximately USD 322,000 per patient per year, which works out to roughly USD 26,800 per month for adult-strength dosing. The UAE dirham (AED) is pegged to the US dollar at approximately 3.67 AED to 1 USD, so monthly drug acquisition translates to roughly AED 98,000 to AED 99,000 at US WAC. The named-patient acquisition cost sits between US WAC and confidential negotiated payer prices in Europe and is finalised only on firm-quote issuance after document review.

International logistics for Trikafta runs at the lower end of the Reserve Meds lane range, typically USD 400 to USD 800 (approximately AED 1,500 to AED 2,950), because the product is ambient-controlled rather than cold-chain. UAE customs and EDE permit handling fees are nominal relative to the drug itself. Reserve Meds' coordination fee is itemised separately on every firm quote. On the insurance side, Daman National Health Insurance (operator of the Thiqa programme for UAE nationals in Abu Dhabi), GIG Gulf, Sukoon Insurance, ADNIC, and Orient Insurance each assess named-patient imports case by case. Several reimburse partially when the medicine is on their formulary even if not currently stocked. Reserve Meds supplies the documentation the insurer needs to assess; the claim itself remains with you or the hospital.

Typical timeline for Trikafta in the UAE

For an established Trikafta patient with a clean F508del genotype letter, a current weight-band confirmation, and a CF center referral, the typical end-to-end cycle is 3 to 6 weeks. The EDE permit step generally runs 5 to 15 business days. US-side sourcing and release through the Vertex specialty-pharmacy network adds approximately 1 to 2 weeks. International ambient-controlled transit and UAE customs clearance under the import permit are typically 3 to 7 days. For first-time imports through a smaller importer or for non-F508del responsive-variant cases, the front-end permit step can extend to 4 to 6 weeks. Timelines are presented as typical ranges and not as promises; specific dates are confirmed at firm-quote issuance.

What your physician needs to provide

The clinical justification letter for Trikafta is the centrepiece of the EDE package. For this product the letter typically includes:

• The patient's confirmed cystic fibrosis diagnosis and CFTR genotype (at least one F508del allele documented on the genetic-testing report, or another responsive variant on the current FDA label)
• The patient's current age and weight, with the weight band that determines the appropriate Trikafta strength (adult strength for patients aged 12 and older or pediatric patients 25 kg and above; lower-strength tablet for patients 6 to 11 under 25 kg; granule packets for patients ages 2 to 5 in two weight bands)
• Prior CF treatment history and any prior CFTR-modulator exposure (Kalydeco, Orkambi, Symdeko, or Trikafta itself)
• Justification for why a locally registered alternative is not suitable (often this is continuity of an established response, or absence of a clinically equivalent on-label alternative)
• The dosing plan: morning tablet plus evening tablet 12 hours apart, both with fat-containing food
• The monitoring plan: baseline and periodic liver function tests (ALT, AST, bilirubin) every three months for the first year then annually; baseline and follow-up ophthalmologic examination in pediatric patients for cataracts; medication reconciliation for CYP3A interactions (rifampin and St John's wort contraindicated, strong inhibitors requiring dose reduction)

The treating physician's UAE license must match the emirate of the dispensing facility (DHA for Dubai, DOH for Abu Dhabi, MOHAP for the Northern Emirates, Sharjah Health Authority for Sharjah). Joint-privilege physicians who hold licenses in multiple emirates can file in any emirate where they are credentialed.

Common questions about Trikafta in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover Trikafta? Each insurer assesses named-patient imports case by case. Several reimburse partially when the molecule is on their formulary even if not currently stocked, and Thiqa (Abu Dhabi government-funded plan for UAE nationals) has the broadest specialty coverage in the emirate. We do not promise coverage. We supply the documentation set that lets your insurer assess the case.

Is my DHA-licensed or DOH-licensed pediatric pulmonologist's letter sufficient? Yes. Any UAE-licensed physician practicing in good standing in the emirate of the dispensing facility has signing authority on the clinical justification letter. CF cases are most commonly signed by a pediatric pulmonologist, an adult pulmonologist with CF subspecialty experience, or a CF-center medical director.

What if my child is under 2 years old? Trikafta is approved for patients aged 2 years and older. Reserve Meds will not coordinate intake for a patient outside the FDA-approved age range.

What about Alyftrek? Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) is Vertex's once-daily successor approved by the FDA in December 2024. Trikafta has longer real-world experience, broader international registration, established payer pathways, and in several markets a lower acquisition cost. Switching is a clinician-driven decision and not one Reserve Meds makes.

What is the safety profile? Most common adverse events on the pivotal trials were headache, upper respiratory infection, abdominal pain, rash, and elevated transaminases. Drug-induced liver injury, cataracts in pediatric patients, and hypersensitivity reactions are labeled warnings. Baseline and periodic liver function testing and pediatric ophthalmologic examination are part of the monitoring plan.

Can the medicine be delivered to our home? The dispensing facility must be UAE-licensed. For Trikafta the medicine moves into a hospital outpatient pharmacy or a specialised import pharmacy, and the family collects it from there. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

Where Reserve Meds fits in Trikafta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your CF physician, do not replace the EDE, and do not replace the dispensing pharmacy. For Trikafta specifically we orchestrate the US-side sourcing through the Vertex specialty-pharmacy network, the regulatory documentation kit your physician needs (genotype letter template, dosing reference by weight band, monitoring plan summary), international ambient-controlled logistics under chain-of-custody, and a single named coordinator who carries the family from intake through delivery. F508del genotype documentation, CF-center referral letter, and current weight-band confirmation are mandatory intake artefacts. We do not coordinate off-label use, and we will decline intake for patients without at least one F508del allele or another labeled CFTR-responsive variant.

Next step

If your CF physician has decided Trikafta is the right next step and local stocking is the bottleneck, the named-patient pathway through the EDE is the route. Join the waitlist below and we will confirm eligibility within 24 to 48 hours and route the documentation kit to your physician.

Join the Trikafta waitlist

Reserved for you.